GTBP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GT

Mkt Cap

$12.8M

Volume

54.89K

Next Earnings

November 13th

Loading chart

GT

GTBPGT Biopharma Inc. Common Stock

GTBP

Pay with—

Available Balance0.00

GT

Mkt Cap

$13.3M

Volume

54.88K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyGT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runway into late 2026. The gap between its scientific promise and market valuation presents both opportunity and substantial risk, with near-term catalysts including clinical data updates and financing announcements expected in H2 2026.Benzinga · Jun 2, 2026

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesA new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—are being developed by multiple biotech companies, with over $1.7 billion in dealmaking activity. GT Biopharma's GTB-5550 NK cell engager and Vir Biotechnology's VIR-5500 PSMA-targeted T-cell engager represent leading programs in this emerging therapeutic landscape.GlobeNewswire Inc. · May 14, 2026

THE VISIBILITY INDEX: 5 Companies Solving the Invisible CrisisThe market is shifting focus towards technologies that can detect previously invisible threats across healthcare, resource exploration, and diagnostics, with several companies developing innovative solutions for cardiac care, diabetes treatment, cancer therapy, and mineral exploration.GlobeNewswire Inc. · Dec 15, 2025

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection PointsMultiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.Benzinga · Dec 4, 2025

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGT Biopharma reported progress on its Phase 1 clinical trial for GTB-3650, a TriKE® therapy targeting CD33-expressing hematologic malignancies, with successful advancement to Cohort 4 and no observed safety issues. The company plans to provide a trial update in Q1 2026 and anticipates submitting an IND for GTB-5550 in late December 2025.GlobeNewswire Inc. · Nov 14, 2025

GT Biopharma Announces Exercise of WarrantsGT Biopharma, a clinical-stage immuno-oncology company, announced it has entered into agreements for the exercise of existing warrants and the issuance of new warrants, raising approximately $0.7 million in gross proceeds.GlobeNewswire Inc. · Feb 25, 2025

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ LeukemiaSAN FRANCISCO, CALIFORNIA, June 27, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to start in second half of 2024.GlobeNewswire Inc. · Jun 27, 2024

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesBRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purchase price of $4.35 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue warrants to purchase up to 740,000 shares of common stock. The warrants have an exercise price of $4.35 per share, will be exercisable immediately and will have a term of five years following the date of issuance. The closing of the offering is expected to occur on or about May 23, 2024, subject to the satisfaction of customary closing conditions.GlobeNewswire Inc. · May 21, 2024

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial ResultsBRISBANE, CALIFORNIA, March 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced fourth quarter and full-year 2023 results for the period ended December 31, 2023.GlobeNewswire Inc. · Mar 26, 2024

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day SessionShares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. Cutera posted adjusted loss of $1.36 per share, compared to market estimates for a loss of 94 cents per share. The company’s quarterly sales came in at $49.540 million, versus expectations of $47.500 million, according to data from Benzinga Pro. Cutera shares dipped 26.5% to $1.6899 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Murano Global Investments PLC (NASDAQ: MRNO) shares jumped 147.5% to $23.94 after falling 46% on Thursday. Nova LifeStyle, Inc. (NASDAQ: NVFY) surged 120% to $4.0301 after gaining around 22% on Thursday. BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 50.4% to $0.2256 after the company reported better-than-expected fourth-quarter earnings results. IMAC Holdings, Inc. (NASDAQ: BACK) gained 41.1% to $1.8204. Summit Midstream Partners, LP (NYSE: SMLP) surged 36.1% to $26.45 after the company announced the sale of its Utica position for $625 million. Outlook Therapeutics, Inc. (NASDAQ: OTLK) gained 32.1% to $9.30 after the company announced it received a positive European Union CHMP opinion for ONS-5010 as a treatment for Wet AMD. GT Biopharma, Inc. (NASDAQ: GTBP) gained 27.6% to $4.86. Aemetis, Inc. (NASDAQ: AMTX) rose 21% to $6.21. Aemetis recently announced approval by the U.S. Citizenship and Immigration Services for a $200 million of EB-5 program investment for the Riverbank sustainable aviation fuel, production plant, the dairy renewable natural gas project, the carbon sequestration project and energy efficiency upgrades to the Keyes ethanol plant. Foresight Autonomous Holdings Ltd. (NASDAQ: ...Benzinga · Mar 22, 2024

to start trading

GT

GTBPGT Biopharma Inc. Common Stock

GTBP

Pay with—

Available Balance0.00

Your PositionYou don't own any GTBP yet.

Related Tickers

Earnings